R&D News | pharmaphorum

News

Kristen Fortney, CEO and co-founder of BioAge Labs

Obesity drug developer BioAge raises $198m in IPO

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%.

News

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

News

Surfing on new Duchenne data, Wave charges $175m offering

Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to its highest level in a year and could lead to discussions with re

News

AI firm Generate signs $1bn discovery deal with Novartis

Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis.

News

football going into the net past goalkeeper to score

UCB, Biogen lupus drug scores in phase 3 trial

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of

News

Sanofi's tolebrutinib cuts MS progression by 31% in trial

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data

Obesity drug developer BioAge raises $198m in IPO

MSD hits a hurdle with its LAG-3 programme

Surfing on new Duchenne data, Wave charges $175m offering

AI firm Generate signs $1bn discovery deal with Novartis

UCB, Biogen lupus drug scores in phase 3 trial

Sanofi's tolebrutinib cuts MS progression by 31% in trial

Euro VCs team up to invigorate life sciences ecosystem

How to meet your physicians where they are online

News

Editor's Picks